Early AKI-risk stratification using biomarkers like endostatin could guide future clinical trials and identify subgroups that may benefit from interventions related to haemodynamics and novel pharmacological treatments that have previously failed to show clear benefit. This evidence concerns the gene COL18A1 and acute kidney injury.